{"filings":[{"id":869721,"accession_number":"0001728117-26-000045","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-06-04T23:28:31+00:00","items":["1.01","1.02","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Gossamer Bio exchanges 90.5% of 5% notes for new 7.5% notes, stock, and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$181M of 5% Convertible Senior Notes due 2027 tendered and cancelled (90.5% of outstanding).","Issued $65M of new 7.5% Convertible Senior Secured First Lien Notes due 2030.","Issued 254M common shares, 33.4M prefunded warrants, and 135.8M purchase warrants.","Remaining $18.9M of existing notes outstanding; exchange offer open until June 16, 2026.","Consent solicitation adopted amendments eliminating restrictive covenants in existing indenture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":869728,"accession_number":"0001728117-26-000042","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-06-04T21:34:07+00:00","items":["5.07"],"status":"ready","headline":"Gossamer Bio shareholders re-elect directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Faheem Hasnain re-elected as Class II director with 92.3M for, 26.7M withheld, 45.5M broker non-votes.","Russell Cox re-elected as Class II director with 89.0M for, 30.0M withheld, 45.5M broker non-votes.","Ratification of Ernst & Young as auditor for FY2026 passed: 163.2M for, 1.2M against, 41K abstain.","Advisory vote on named executive officer compensation approved: 111.3M for, 7.5M against, 137K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787917,"accession_number":"0001728117-26-000040","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-06-02T12:00:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Gossamer Bio extends early tender deadline for exchange offer; $181M of notes tendered","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Early tender deadline extended to 5:00 p.m. ET on June 2, 2026; early settlement expected June 4, 2026.","$181,052,000 in aggregate principal of 5.00% Convertible Senior Notes due 2027 validly tendered as of June 1.","Exchange offer requires minimum 98% of aggregate principal to be tendered; withdrawal deadline expired June 1.","New 7.50% Convertible Senior Secured First Lien Notes due 2030 offered, up to $72.0M principal.","Up to 317,647,058 shares of common stock (or prefunded warrants) offered as part of exchange consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":481996,"accession_number":"0001728117-26-000036","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-05-18T11:06:58+00:00","items":["1.01","2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Gossamer Bio launches exchange offer for 5.00% notes; holders of 75.2% support","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchange Offer: up to $72M new 7.50% Convertible Secured Notes due 2030, plus up to 317.6M common shares and 150M Purchase Warrants.","Supporting Noteholders holding 75.2% of existing notes agree to tender and consent to indenture amendments.","Conditions include minimum 98% participation; early settlement expected June 3, final June 18, 2026.","Also filed Q1 2026 financial results (press release not provided in filing text).","Stockholder proposals include increasing authorized shares from 700M to 4B and reverse stock split (1:10 to 1:150)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95038,"accession_number":"0001728117-26-000022","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gossamer Bio receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Gossamer on April 8, 2026 that stock bid price <$1.00 for 30 consecutive business days (Feb 24 – Apr 7, 2026).","Company has 180 calendar days, until Oct 5, 2026, to regain compliance by closing bid >=$1.00 for 10 consecutive business days.","If not cured by Oct 5, may transfer to Nasdaq Capital Market for additional 180-day compliance period if eligible.","Company will monitor price and consider options including reverse stock split if needed.","No assurance of regaining compliance; potential delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107824,"accession_number":"0001728117-26-000018","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio reports 2025 net loss $170.4M; seralutinib Phase 3 narrowly missed primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PROSERA Phase 3 in PAH showed placebo-adjusted 6MWD +13.3 meters but missed prespecified statistical alpha of 0.025 (p=0.0320).","Enrollment in Phase 3 SERANATA (PH-ILD) paused; Company evaluating implications and plans FDA Type C meeting in June 2026.","Implemented reduction in force and cost-containment measures to align resources with near-term priorities.","Cash, equivalents and marketable securities $136.9M at Dec 31, 2025; expected to fund operations into Q1 2027.","Net loss for FY2025 was $170.4M ($0.75 per share) compared to $56.5M ($0.25 per share) in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107823,"accession_number":"0001728117-26-000004","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Gossamer Bio Phase 3 PROSERA trial misses primary endpoint, seralutinib shows signals in high-risk PAH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary 6MWD endpoint missed: +13.3m placebo-adjusted (p=0.0320 vs prespecified α=0.025).","Four key secondary endpoints favored seralutinib; NT-proBNP reduced 120.4 ng/L (p=0.0002).","In intermediate/high-risk (REVEAL Lite 2 ≥6, n=234), 6MWD gain +20.0m (p=0.0207).","Gossamer to meet with FDA to discuss path forward; pauses SERANATA study enrollment.","Seralutinib well tolerated; cough (37%) and transaminase elevations >3x ULN (13%) reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124220,"accession_number":"0001728117-25-000082","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q3 net loss $48.2M; PROSERA topline due Feb 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $48.2M ($0.21 per share) vs $30.8M loss a year ago; revenue from Chiesi collab $13.3M.","Cash, cash equivalents and marketable securities $180.2M; sufficient to fund ops into 2027.","PROSERA Phase 3 PAH study enrollment complete (390 pts); topline results expected February 2026.","First site activated for SERANATA Phase 3 PH-ILD study; targeting enrollment of ~480 patients.","Strategic option agreement to acquire Respira via 1.5M shares; no new trials expected before 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":34672000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140887,"accession_number":"0001728117-25-000076","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Gossamer Bio issues 2.5M shares for option to acquire Respira Therapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,500,000 shares to Prana Bio on Sept 24, 2025 as consideration for option to acquire Respira via merger.","Option exercisable until Dec 31, 2027 or earlier upon completion of certain Respira development activities.","May issue up to 1.5M additional shares upon exercise, plus up to ~6.7M shares on regulatory and sales milestones.","Shares issued in reliance on Section 4(a)(2) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140886,"accession_number":"0001728117-25-000069","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q2 net loss $38.3M; PROSERA Phase 3 topline due Feb 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.3M ($0.17 per share) vs net income $49.2M in Q2 2024, driven by $88.8M one-time license revenue in prior year.","Cash, equivalents and marketable securities $212.9M as of June 30, 2025; runway into 2027.","PROSERA Phase 3 PAH study enrolled 390 patients; topline results expected February 2026.","SERANATA Phase 3 PH-ILD study first site activations planned Q4 2025; 480-patient, 24-week trial.","Collaboration revenue $11.5M (mostly cost reimbursement from Chiesi) vs $95.8M in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":21378000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158638,"accession_number":"0001728117-25-000043","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Stockholders re-elect three Class I directors, approve amended incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors re-elected: Thomas Daniel, Sandra Milligan, Steven Nathan.","Ratification of Ernst & Young as auditor for FY2025 approved (176.5M for, 98k against).","Advisory vote on named executive officer compensation approved (125.4M for, 3.8M against).","Amended and Restated 2019 Incentive Award Plan approved (87.8M for, 41.5M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158637,"accession_number":"0001728117-25-000040","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gossamer Bio completes enrollment in Phase 3 PROSERA study for seralutinib in PAH (n=390)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Global registrational Phase 3 PROSERA study fully enrolled; topline results expected February 2026.","Enrolled 390 patients vs 86 in Phase 2; mean 6MWD 374 m (vs 408 m), NT-proBNP 987 ng/L (vs 628).","74% of patients are Functional Class III vs 42% in Phase 2; enrichment criteria applied to target responders.","Study is double-blind, placebo-controlled, primary endpoint change in 6MWD at week 24.","Seralutinib developed with Chiesi Group; positive milestone for first-in-class PAH treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158636,"accession_number":"0001728117-25-000037","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio closes new patient screening in PAH Phase 3 PROSERA study; Q1 net loss $36.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Enrollment of 343 patients completed; to exceed 350 by early June; topline results expected Feb 2026.","Baseline characteristics align with target: mean 6MWD 376 m, 74% Functional Class III, NT-proBNP 986 ng/L.","Phase 3 SERANATA study in PH-ILD to begin site activations in Q4 2025 with ~480 patients.","Cash $257.9M expected to fund operations into H1 2027; Q1 net loss $36.6M ($0.16/share).","Revenue from Chiesi collaboration $9.9M ($6.6M cost reimbursement); R&D expenses $38.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":9889000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177039,"accession_number":"0001728117-25-000022","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q4 2024 net loss $33M; PROSERA Phase 3 topline due Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $294.5M at year-end; runway into H1 2027.","Full-year 2024 net loss $56.5M ($0.25/share) vs $179.8M ($1.18) in 2023.","R&D expenses $138.5M in 2024 vs $135.3M in 2023; G&A $36.1M vs $38.5M.","PROSERA Phase 3 in PAH on track for topline data readout in Q4 2025.","PH-ILD registrational Phase 3 to commence H2 2025; seralutinib got Japan orphan PAH designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177038,"accession_number":"0001728117-25-000004","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gossamer Bio regains Nasdaq minimum bid price compliance; deficiency closed.","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 19, 2025 confirming regained compliance with minimum bid price rule.","Previously notified of deficiency on Sept 11, 2024 for failing to maintain $1.00 bid price for 30 days.","Compliance matter now closed; common stock remains listed on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193808,"accession_number":"0001728117-24-000093","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q3 net loss $30.8M; cash $327M, runway into H1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.8M ($0.14/share) vs $40.0M ($0.21/share) in Q3 2023; revenue from Chiesi collaboration was $9.5M.","Cash, cash equivalents & marketable securities $327M as of Sept 30, 2024; expected to fund operations into H1 2027.","Phase 3 PROSERA trial in PAH enrollment ongoing; topline results expected Q4 2025.","Expect to commence global registrational Phase 3 trial for PH-ILD in mid-2025.","R&D expenses $34.9M (up from $31.2M); G&A $8.5M (down from $9.3M) YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":105322000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210147,"accession_number":"0001728117-24-000088","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gossamer Bio receives Nasdaq bid-price deficiency notice; deadline March 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Gossamer Bio that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sept 10, 2024.","Company has 180 calendar days, until March 10, 2025, to regain compliance by closing at $1.00 for at least 10 consecutive business days.","If not compliant by March 2025, may transfer to Nasdaq Capital Market for an additional 180-day cure period, subject to other standards.","Company may consider options such as a reverse stock split but cannot guarantee it will regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210146,"accession_number":"0001728117-24-000086","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q2 2024 net income $49.2M; cash $354.5M; Chiesi collaboration on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $49.2M ($0.22 basic EPS) vs net loss $42.5M in Q2 2023.","Cash, cash equivalents & marketable securities $354.5M as of June 30, 2024; runway into H1 2027.","Revenue from Chiesi collaboration: $88.8M license sale + $7.1M R&D services.","R&D expenses $35.1M (vs $36.3M); G&A expenses $8.7M (vs $10.0M).","PROSERA Phase 3 PAH trial enrollment ongoing; top-line results expected Q4 2025; Phase 3 PH-ILD trial to start mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":95842000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210145,"accession_number":"0001728117-24-000080","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gossamer Bio regains Nasdaq minimum bid price compliance; listing matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 18, 2024 confirming regained compliance with minimum bid price rule.","Previous non-compliance notice dated May 22, 2024; stock had failed to maintain $1.00 minimum bid for 30 consecutive days.","The minimum bid price deficiency is now resolved; Nasdaq has closed the matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228392,"accession_number":"0001728117-24-000069","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Gossamer Bio reports annual meeting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Skye Drynan and John Quisel re-elected as Class II directors for three-year terms.","Ernst & Young LLP ratified as independent auditor for FY2024 with 189.7M for, 1.2M against.","Advisory vote on executive compensation approved with 116.0M for, 40.4M against, 5.8M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228391,"accession_number":"0001728117-24-000059","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gossamer Bio receives Nasdaq minimum bid deficiency; cure period to Nov 18, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notice on May 22, 2024; stock below $1.00 for 30 consecutive business days through May 21.","Company has 180 calendar days, until November 18, 2024, to regain compliance.","To cure, closing bid must be at least $1.00 for ten consecutive business days.","If not cured, may transfer to Nasdaq Capital Market for additional 180 days or face delisting.","Company may consider a reverse stock split to address the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228390,"accession_number":"0001728117-24-000057","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio reports Q1 net loss $41.9M; announces Chiesi collaboration for seralutinib","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Chiesi collaboration provides $160M upfront; Gossamer and Chiesi split global development costs, profits in US.","Pro forma cash, cash equivalents and marketable securities $396M as of March 31, 2024.","PROSERA Phase 3 PAH study topline results expected Q4 2025; registrational Phase 3 PH-ILD to start mid-2025.","Net loss $41.9M ($0.19 per share) for Q1 2024 vs $49.2M ($0.52 per share) in Q1 2023.","R&D expenses $32.4M in Q1 2024 down from $37.8M YoY, primarily due to terminated programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228389,"accession_number":"0001728117-24-000052","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["1.01","1.02","3.02","8.01","9.01"],"status":"ready","headline":"Gossamer Bio enters global collaboration with Chiesi for seralutinib; receives $160M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Receives $160M development reimbursement; eligible for up to $146M regulatory and $180M sales milestones.","Gossamer leads US commercialization for PAH/PH-ILD with 50/50 profit split; Chiesi obtains ex-US rights with tiered royalties.","Companies plan to initiate Phase 3 registrational study of seralutinib in PH-ILD in mid-2025.","Existing MidCap credit facility terminated and repaid in full upon deal closing.","Chiesi receives equity option to purchase up to 9.9% of Gossamer at 107.5% of VWAP, min $1.63/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247098,"accession_number":"0001728117-24-000024","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Gossamer Bio appoints Dr. Nathan (PH-ILD expert) and biotech analyst Drynan to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Steven Nathan appointed as Class I director, effective March 11, 2024; brings pulmonary and PH-ILD expertise.","Skye Drynan appointed as Class III director; former Capital Group Partner and Senior BioPharma Analyst.","Each new director receives $40,000 annual cash retainer and option for 230,000 shares vesting over three years.","Dr. Nathan's guidance intended to support expansion of seralutinib clinical program into PH-ILD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247097,"accession_number":"0001728117-24-000018","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q4/FY23 results: first PAH patient dosed in Phase 3 PROSERA, cash $296M into H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First PAH patient dosed in registrational Phase 3 PROSERA study; topline results expected Q4 2025.","Japan PMDA accepted CTN, allowing inclusion of Japanese sites without PK bridging; could support Japanese NDA.","Cash, equivalents & marketable securities $296.4M at Dec 31, 2023; expected to fund operations into H1 2026.","Net loss for FY2023: $179.8M ($1.18 per share) vs $229.4M ($2.71) in FY2022.","R&D expenses FY2023: $135.3M vs $170.9M in FY2022; G&A: $38.5M vs $47.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247096,"accession_number":"0001728117-24-000013","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gossamer Bio regains Nasdaq minimum bid price compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on March 4, 2024 confirming compliance with minimum bid price rule.","Common stock had failed to maintain $1.00 bid price for 30 consecutive days as of Oct 2023.","Nasdaq listing qualification matter is now closed.","Compliance regained with Nasdaq Global Select Market listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}